

| Award Mechanism | Eligibility | Key Mechanism Elements | Funding | Submission Deadline |
|--|--|--|--|--|
| <p>Innovator Award II</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>W81XWH-17-BCRP-INNOV2</p> | <ul style="list-style-type: none"> • Must be an Associate Professor or above (or equivalent). | <ul style="list-style-type: none"> • Supports visionary individuals who have demonstrated creativity, innovative work, and leadership in any field. • Provides opportunity to pursue novel, visionary, high-risk ideas that will accelerate progress toward ending breast cancer. • Experience in breast cancer research is not required; however, the application must focus on breast cancer, and the PI must maintain a 50% dedication of his/her full-time professional effort during the award period to breast cancer research. • PIs must include breast cancer advocates on their research team. • <i>Preproposal is required; application submission is by invitation only.</i> | <ul style="list-style-type: none"> • Maximum funding of \$5M for direct costs (plus indirect costs). • The maximum period of performance is 4 years. | <p>Pre-Application: October 6, 2017, 5:00 p.m. ET</p> <p>Confidential Letters of Recommendation Submission Deadline: December 29, 2017, 5:00 p.m. ET</p> <p>Invited Application: December 27, 2017, 11:59 p.m. ET</p> |

| Award Mechanism | Eligibility | Key Mechanism Elements | Funding | Submission Deadline |
|--|---|--|--|--|
| <p>Breakthrough Levels 3 and 4 Award II</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>W81XWH-17-BCRP-BREAKTHROUGH2-FL34</p> | <ul style="list-style-type: none"> • Independent investigators at all academic levels (or equivalent) are eligible. • Each investigator may submit only one Funding Level 3 pre-application and one Funding Level 4 pre-application as a PI or Initiating PI. | <ul style="list-style-type: none"> • Supports promising research that has the potential to lead to or make breakthroughs in breast cancer. • Potential impact of the research may be near-term or long-term, but it must be significant and go beyond an incremental advancement. • Partnering PI Option allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application. • It is the responsibility of the PI to select the funding level that is most appropriate for the research proposed. The funding level should be selected based on the scope of the research project, rather than the amount of the budget. • Clinical trials are allowed. • There are no limitations on the number of applications for which an investigator may be named as a Partnering PI. However, applicants are discouraged from submitting as a Partnering PI on multiple applications unless they are clearly unique, meaningful collaborations addressing distinct research questions. • PIs must include two or more breast cancer advocates on their research team. • Submission of a preproposal is required; <i>application submission is by invitation only.</i> | <p>Funding Level 3:</p> <ul style="list-style-type: none"> • Maximum funding of \$2.5M in direct costs (plus indirect costs). • The maximum period of performance is 4 years. <p>Funding Level 3 with Partnering PI Option:</p> <ul style="list-style-type: none"> • Maximum funding of \$4M for direct costs (plus indirect costs). • The maximum period of performance is 4 years. <p>Funding Level 4 and Funding Level 4 Partnering PI Option:</p> <ul style="list-style-type: none"> • Maximum funding of \$10M for direct costs (plus indirect costs). • The maximum period of performance is 4 years. | <p>Pre-Application (Preproposal): October 6, 2017, 5:00 p.m. ET</p> <p>Invited Application: December 27, 2017, 11:59 p.m. ET</p> |

| Award Mechanism | Eligibility | Key Mechanism Elements | Funding | Submission Deadline |
|---|--|--|--|--|
| <p>Distinguished Investigator Award II</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>W81XWH-17-BCRP-DIA2</p> | <ul style="list-style-type: none"> • PIs must be at or above the level of Assistant Professor (or equivalent) and be more than 6 years beyond their last mentored position as of the application submission deadline. | <ul style="list-style-type: none"> • Supports established visionary leaders from any field to pursue innovative ideas that could accelerate progress toward ending breast cancer. • The PI must propose research that is a fundamental shift from his/her track record of research. • Does not support continuation of or incremental change from the PI's published line of research. • If the PI is not an established breast cancer researcher, he/she must clearly articulate a motivation and commitment for proposing a fundamental shift in his/her research and must include at least one collaborator with breast cancer expertise. • High-risk/high-reward projects pursuing innovative new paradigms are encouraged, but not required. • PIs must include two or more breast cancer advocates on their research team. • Submission of a preproposal is required; <i>application submission is by invitation only.</i> | <ul style="list-style-type: none"> • Maximum funding of \$3M for direct costs (plus indirect costs). • The maximum period of performance is 4 years. | <p>Pre-Application (Preproposal): October 6, 2017, 5:00 p.m. ET</p> <p>Confidential Letters of Recommendation Submission Deadline: December 29, 2017, 5:00 p.m. ET</p> <p>Invited Application: December 27, 2017, 11:59 p.m. ET</p> |